Barinthus Biotherapeutics (BRNS) Institutional Ownership → AI's Next Magnificent Seven (From The Oxford Club) (Ad) Free BRNS Stock Alerts $1.99 +0.10 (+5.01%) (As of 06/7/2024 08:51 PM ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Barinthus Biotherapeutics (NASDAQ:BRNS)CurrentInstitutional OwnershipPercentage25.20%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$2.82MNumber ofInstitutional Sellers(last 12 months)0 Get BRNS Insider Trade Alerts Want to know when executives and insiders are buying or selling Barinthus Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. Barinthus Biotherapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/16/2024 BlueCrest Capital Management Ltd542,673$1.29M0.1%N/A1.394% 5/14/2024 DC Funds LP642,204$1.53M14.8%N/A1.650% (Data available from 1/1/2016 forward) BRNS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of BRNS shares? During the previous two years, the following institutional investors and hedge funds held shares of Barinthus Biotherapeutics shares: DC Funds LP ($1.53M), BlueCrest Capital Management Ltd ($1.29M).Learn more on BRNS's institutional investors. What percentage of Barinthus Biotherapeutics stock is owned by institutional investors? 25.20% of Barinthus Biotherapeutics stock is owned by institutional investors. Learn more on BRNS's institutional investor holdings. Which institutional investors have been buying Barinthus Biotherapeutics stock? The following institutional investors have purchased Barinthus Biotherapeutics stock in the last 24 months: DC Funds LP ($642.20K), and BlueCrest Capital Management Ltd ($542.67K). How much institutional buying is happening at Barinthus Biotherapeutics? Institutional investors have bought a total of 1,184,877 shares in the last 24 months. This purchase volume represents approximately $2.82M in transactions. Related Companies: KMDA Institutional Ownership AVIR Institutional Ownership RVNC Institutional Ownership EPIX Institutional Ownership XOMA Institutional Ownership MRSN Institutional Ownership VNDA Institutional Ownership CRMD Institutional Ownership INZY Institutional Ownership ANL Institutional Ownership This page (NASDAQ:BRNS) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.